Brent Ristow, CEO of Brighton Ashford, leverages his legal and scientific expertise to ensure FDA compliance for pharmaceuticals and medical devices. With a background in law and a Ph.D. in Organic Photochemistry, Brent Ristow's company delivers meticulous testing conforming to Title 21 standards and cGMP guidelines. Trusted by Fortune 500 firms and startups alike, Brighton Ashford exceeds regulatory expectations under Ristow's leadership. From performance testing to regulatory submissions, Brent Ristow's blend of legal acumen and scientific rigor sets Brighton Ashford apart in the industry.
Recent Updates
-
Brent Ristow | Brent Alan Ristow | Brighton AshfordNon-Volatiles Analysis in Medical Device Extractables & Leachables Testing White Paper by , Brent Ristow, PhD, JD On February 20, 2024 the FDA released a letter titled “Fraudulent and Unreliable Laboratory Testing Data in Premarket Submissions … reminding sponsors of device studies and manufacturers of devices to carefully evaluate the third parties they engage to...0 Comments 0 Shares 459 Views 0 ReviewsPlease log in to like, share and comment!
-
-
0 Comments 0 Shares 186 Views 0 Reviews
More Stories